Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

End-of-life care promotes compassion by granting wishes of dying patients, families

24 Nov 2019
Appropriate policies are required to facilitate and integrate palliative care in healthcare systems, and finance proper training for developing human resources.

The 3 Wishes Project (3WP), a “transferable, affordable and sustainable” palliative intervention, has been successfully implemented, providing value to dying patients, their families, clinicians and institutions, a recent study has shown.

“The 3WP is an end-of-life programme that aims to honour the dignity of dying patients by creating meaningful patient- and family-centred memories while promoting humanistic interprofessional care,” the authors said.

In total, 730 patients were included, eliciting 3,407 wishes. Qualitative data were obtained from 75 family members, 72 clinicians and 20 managers or hospital administrators.

One value created by the 3WP was the intentional comforting of families as they honoured the lives and legacies of their loved ones while inspiring compassionate clinical care. Factors that encouraged transferability of the programme included family appreciation and a collaborative intensive care unit (ICU) culture committed to dignity-conserving end-of-life care.

Moreover, participation of the staff evolved from passive support to professional agency.

Initiating the 3WP required minimal investment for reusable materials. Subsequently, the mean cost was $5.19 per wish. The continuation of 3WP at each site after study completion demonstrated the programme’s sustainability.

This mixed-methods formative programme evaluation included dying patients, their families, clinicians, hospital managers and administrators from four North American ICUs. The intervention elicited and implemented wishes from dying patients, family members and clinicians.

Measurements included patient characteristics and care processes; number, type and cost of each wish; and semistructured interviews and focus groups with family members, clinicians and managers.

This descriptive formative evaluation describes tertiary care centre–specific experiences rather than aiming for generalizability to all jurisdictions,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.